An observational study in Growth Hormone Deficiency, sponsored by University of Parma. Recruiting at 1 site in Italy. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2024-06-13.
Sponsored by University of Parma · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Dwarfism, Pituitary with a site in Italy — 2 open to participants now, 2 under way, none of them phase 3. Dwarfism, Pituitary · Italy.
Among the 28 studies in Dwarfism, Pituitary with a site in Italy, this one is one of 2 that started in 2023, is one of 8 observational ones, and was the 27th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →2 of the 28 studies in Dwarfism, Pituitary with a site in Italy are open now. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 5–18
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 2 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 70 across 73 observational studies indexed under Dwarfism, Pituitary.
Median enrollment 83 across the 19 interventional studies, 38 across the 8 observational. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 28 have an industry lead sponsor. The 10 most frequent:
University of Parma is the lead sponsor of 77 studies on the registry; 8 are open to participants now.
University of Parma has 1 study filed under Dwarfism, Pituitary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Dwarfism, Pituitary with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.
In 200 prepubertal and pubertal subjects with the suspicion of GHD, the levels of three specific circulating miRNas will be measured to establish whether they can be used for the diagnosis of GH deficiency. In subjects with isolated idiopathic GHD (IIGHD), short statured patients born SGA, Noonan and Turner syndromes, and SHOX deficiency, we will also assess the changes of the identified miRNAs before and after 3 months on GH therapy to verify an early growth prediction model for growth response at 12 months on treatment. Finally, we plan to identify any differences in these miRNAs at 3 months on treatment using daily GH versus weekly (long-acting) GH.
All patients will be investigated in routine practice during the normal workup for short stature and stunted growth. Treatment will be also delivered accordind to standard care indications and as established by regulatory agencies in Italy.
Inclusion Criteria for aim 1:
Exclusion criteria for aim 1:
-Subjects with underlying genetic conditions and chronic diseases
Inclusion Criteria for aim 2-3-5:
Inclusion Criteria for aim 4:
Assessing new biomarkers for the diagnosis of GHD
The 1st objective will consist in the enrolment of 200 subjects, nationwide, undergoing standard routine work-up for the diagnosis of GHD. The specific miRNAs will be measured at the time of both stimulation tests in order to include subjects with both confirmed and unconfirmed GHD and guarantee reproducibility; in addition, subjects with organic GH deficiency will be included.
Time frame: 3 years
Measuring miRNA changes after 3 months on GH therapy
The 2nd objective will consist in measuring these specific miRNAs before and at 3 months on treatment in 200 subjects with isolated idiopathic GHD(IIGHD), and in 60 short statured patients born SGA, in 60 having Noonan and Turner syndromes, and in 30 with SHOX deficiency, according to current indications to verify whether changes are confirmed in pubertal versus prepubertal subjects and in conditions other than IIGHD.
Time frame: 3 years
Multiple linear regression models
The 3rd objective will consist in investigating the major determinants of height variations between 0 and 6 months, 0 and 12 months and the variance of growth rate variation between 0 and 6 months including the levels and/or changes in the specific miRNAs at baseline and at 3 months on treatment by using multiple linear regression models to establish early prediction models of growth response..
Time frame: 3 years
Measuring miRNA changes between daily and long-acting GH therapy
The 4th objective will consist in measuring these specific miRNAs before and at 3 months on treatment in children with IIGHD being treated with daily versus longacting GH. Findings will be compared with those in the IIGHD group receiving daily GH treatment as an exploratory task, thus, only a small number of subjects will be enrolled, and anyway as many as possible.
Time frame: 3 years
Sex-specific miRNA changes after 3 months on long-acting GH therapy
Any differences between males and females in miRNAs expression after 3 months of long-acting GH therapy will be evaluated.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Mar 2025, 23 months after the start.
Of 30 observational studies under Dwarfism, Pituitary, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 102. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Parma